Twist Bioscience Corp Stock Alpha and Beta Analysis
| TWST Stock | USD 43.62 0.99 2.22% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Twist Bioscience Corp. It also helps investors analyze the systematic and unsystematic risks associated with investing in Twist Bioscience over a specified time horizon. Remember, high Twist Bioscience's alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Twist Bioscience's market risk premium analysis include:
Beta 2.59 | Alpha (0.11) | Risk 3.87 | Sharpe Ratio 0.0035 | Expected Return 0.0134 |
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Twist |
Twist Bioscience Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Twist Bioscience market risk premium is the additional return an investor will receive from holding Twist Bioscience long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Twist Bioscience. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Twist Bioscience's performance over market.| α | -0.11 | β | 2.59 |
Twist Bioscience expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Twist Bioscience's Buy-and-hold return. Our buy-and-hold chart shows how Twist Bioscience performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Twist Bioscience Market Price Analysis
Market price analysis indicators help investors to evaluate how Twist Bioscience stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Twist Bioscience shares will generate the highest return on investment. By understating and applying Twist Bioscience stock market price indicators, traders can identify Twist Bioscience position entry and exit signals to maximize returns.
Twist Bioscience Return and Market Media
The median price of Twist Bioscience for the period between Sat, Sep 21, 2024 and Fri, Dec 20, 2024 is 45.29 with a coefficient of variation of 7.57. The daily time series for the period is distributed with a sample standard deviation of 3.41, arithmetic mean of 45.05, and mean deviation of 2.76. The Stock received a lot of media exposure during the period. Price Growth (%) |
| Timeline |
1 | Disposition of 3104 shares by Dennis Cho of Twist Bioscience at 43.211 subject to Rule 16b-3 | 10/02/2024 |
2 | Disposition of 856 shares by Adam Laponis of Twist Bioscience at 41.812 subject to Rule 16b-3 | 10/09/2024 |
3 | Acquisition by William Banyai of 41455 shares of Twist Bioscience subject to Rule 16b-3 | 10/21/2024 |
4 | Disposition of 156 shares by Robert Werner of Twist Bioscience at 41.564 subject to Rule 16b-3 | 11/04/2024 |
5 | Twist Bioscience CEO Emily Leproust sells 201,211 in stock | 11/06/2024 |
6 | Disposition of 7968 shares by Emily Leproust of Twist Bioscience at 47.998 subject to Rule 16b-3 | 11/11/2024 |
7 | Twist Bioscience Corp Trading Down 3.52 percent on Nov 14 | 11/14/2024 |
8 | Twist Bioscience Corp Q4 2024 Earnings Call Highlights Record Revenue Growth and ... | 11/19/2024 |
9 | Disposition of 789 shares by Robert Werner of Twist Bioscience at 44.196 subject to Rule 16b-3 | 11/25/2024 |
10 | Is Agios Pharmaceuticals Stock Outpacing Its Medical Peers This Year | 11/26/2024 |
11 | Twist Bioscience stock gets Outperform rating from Baird, pricing premiums remain elevated | 12/03/2024 |
12 | Disposition of 226 shares by Robert Werner of Twist Bioscience at 52.704 subject to Rule 16b-3 | 12/06/2024 |
13 | Why Twist Bioscience Is the Worst ARK Stock to Buy According to Short Sellers | 12/11/2024 |
14 | Twist Bioscience Co. CAO Sells 11,910.20 in Stock | 12/13/2024 |
15 | Disposition of 133 shares by Dennis Cho of Twist Bioscience at 46.807 subject to Rule 16b-3 | 12/16/2024 |
16 | Twist Bioscience Corp to Present at J.P. Morgan Healthcare Conference | 12/19/2024 |
About Twist Bioscience Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Twist or other stocks. Alpha measures the amount that position in Twist Bioscience Corp has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2021 | 2022 | 2023 | 2024 (projected) | Payables Turnover | 5.94 | 11.06 | 110.2 | 115.71 | Days Of Inventory On Hand | 120.23 | 75.32 | 48.93 | 58.81 |
Twist Bioscience Upcoming Company Events
As portrayed in its financial statements, the presentation of Twist Bioscience's financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Twist Bioscience's leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Twist Bioscience's public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Twist Bioscience. Please utilize our Beneish M Score to check the likelihood of Twist Bioscience's management manipulating its earnings.
| 2nd of February 2024 Upcoming Quarterly Report | View | |
| 3rd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 15th of November 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 30th of September 2023 Last Financial Announcement | View |
Build Portfolio with Twist Bioscience
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Additional Tools for Twist Stock Analysis
When running Twist Bioscience's price analysis, check to measure Twist Bioscience's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Twist Bioscience is operating at the current time. Most of Twist Bioscience's value examination focuses on studying past and present price action to predict the probability of Twist Bioscience's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Twist Bioscience's price. Additionally, you may evaluate how the addition of Twist Bioscience to your portfolios can decrease your overall portfolio volatility.